Composition and device for preventing hypoglycemia and use thereof
A composition for preventing or treating hypoglycemia in a patient in need thereof has a microgel that includes crosslinked polymers containing glucose-responsive moieties; and blood glucose-raising therapeutic agent loaded on or within the microgel. The microgel further includes any one or a combination of a stabilizing component and a loading-assisting component for the blood glucose-raising therapeutic agent. The polymers containing the glucose-responsive moieties form secondary crosslinks in response to low glucose level, thereby causing shrinking of the microgel and rapid release of the blood glucose-raising therapeutic agent. The composition can be used to prepare a composite microneedle patch for preventing or treating hypoglycemia, where the composition is embedded or integrated within an array of the microneedles of the microneedle patch device.
1. A composition for blocking or treating hypoglycemia comprising:
a microgel comprising crosslinked polymers containing glucose-responsive moieties; and
a blood glucose-raising therapeutic agent loaded on or within the microgel,
wherein the microgel further comprises a stabilizing component for the blood glucose-raising therapeutic agent,
wherein the stabilizing component is zwitterionic-based polymers, and the blood glucose-raising therapeutic agent is native glucagon.
2. The composition of claim 1 wherein polymers containing the glucose-responsive moieties form secondary crosslinks in response to low glucose level, thereby causing shrinking of the microgel and rapid release of the blood glucose-raising therapeutic agent.
3. The composition of claim 1 wherein the glucose-responsive moieties are any one or a combination of a boronic acid-containing compound, glucose oxidase, and lectin.
4. The composition of claim 3 wherein the boronic acid-containing compound is a polymer containing any one or a combination of 4-mercaptophenylboronic acid, phenylboronic acid, 3-alkylamidophenylboronic acid, 4-carboxyphenylboronic acid, 4-acetamido-3-fluorophenylboronic acid, 2-hydroxymethylphenylboronic acid, 4-nitrophenylboronic acid, 3-acetamido-6-heptafluoropropylphenylboronic acid, 4-vinylphenylboronic acid, 3-acrylamidophenylboronic acid, 4-(1,6-dioxo-2,5-diaza-7-oxamyl)phenylboronic acid, 2-dimethylaminomethyl-5-vinylphenylboronic acid, 4-(N-allylsulfamoyl) phenylboronic acid, 4-(3-butenylsulfonyl)phenylboronic acid and 4-acrylamido-3-fluorophenylboronic acid (AFBA).
5. The composition of claim 3 , wherein the boronic acid-containing compound is AFBA.
6. The composition of claim 3 wherein the lectin is Concanavalin A.
7. The composition of claim 1 , wherein the stabilizing component protects the therapeutic agent during loading onto and release from the microgels, and during the manufacturing of a device having the microgels embedded or integrated, and storage and clinical applications of the device.
8. The composition of claim 1 wherein the stabilizing component stabilizes the native structure and bioactivity of the therapeutic agent.
9. The composition of claim 1 wherein the zwitterionic-based polymers are polymers of N-(methacryloxypropyl)-N, N-dimethyl-N-(3-sulfopropyl) ammonium betaine, and cationic carboxybetaine.
10. The composition of claim 1 wherein the zwitterionic-based polymers are zwitterionic polymers bearing carboxybetaine and sulfobetaine.
11. The composition of claim 1 further comprising a loading-assisting component selected from the group consisting of (2-carboxymethyl)-3 acrylamidopropyldimethylammonium bromide methyl ester, (4-carboxypropyl)-3-acrylamidopropyldimethylammonium bromide ethyl ester, (6-carboxypentyl)-3-acrylamidopropyldimethylammonium bromide ethyl ester, 3-acrylamido-N-(2-methoxy-2-oxoethyl)-N,N-dimethylpropan-1-aminium, 3-methacrylamido-N-(2-methoxy-2-oxoethyl)-N, N-dimethylpropan-1-aminium 2-Carboxy-N, N,-dimethyl-N-(2′-(methacryloyloxy) ethyl) ethanaminium inner salt and 3-[2-(Methacryloyloxy) ethyl]dimethylammonio]propionate.
12. The composition of claim 11 wherein the crosslinked polymer has an opposite ionic charge with respect to therapeutic agent at selected pH and is converted to zwitterionic form after hydrolysis.
13. The composition of claim 1 wherein the therapeutic agent regulates hypoglycemia.
14. The composition of claim 1 wherein monomer units in the crosslinked polymers are crosslinked with physical or chemical linkages that are biodegradable or non-degradable.
15. The composition of claim 14 wherein the cross-linkages are selected from group of N,N′-Methylenbis-acrylamide, dimethylsubermidate, glutaraldehyde, N,N-ethylene-bis (iodoacetamide), ethylene glycol dimethacrylate, poly(ε-caprolactone) diacrylate, polylactide diacrylate, polylactide dimethacrylate, poly(lactide-co-glycolide) diacrylate, poly(lactide-co-glycolide) dimethacrylate, poly(ε-caprolactone-b-ethylene glycol-b-ε-caprolactone) diacrylate, glycol-b-(lactide-co-glycolide)] dimethacrylate, and polymerizable compounds containing disulfide bonds, peptide bonds, or ester bonds.
16. The composition of claim 1 , wherein monomer units in the crosslinked polymers are crosslinked with N,N′-methylenebisacrylamide.
17. The composition of claim 1 , wherein the microgel is a multifunctional microgel having a particle size of about 20 nm to 1000 μm.
18. The composition of claim 1 wherein the blood glucose-raising therapeutic agent is loaded by:
dissolving, dispersing, entrapping, or encapsulating within, or attachment on the glucose-responsive microgels.